论文部分内容阅读
目的观察力尔凡联合GP方案治疗晚期非小细胞肺癌(NSCLC)的疗效及护理措施。方法晚期NSCLC患者32例随机分为治疗组和对照组,分别以力尔凡加GP方案和GP方案治疗。对照组和治疗组均在连续2个化疗周期后进行疗效评价。结果治疗组16例,PR 7例,SD 8例,PD1例,有效率(CR+PR)为43.8%;对照组中可评价病例数为15例,其中PR 5例,SD 7例,PD 3例,有效率为33.3%。治疗组患者发热反应较对照组偏高,其他不良反应明显低于对照组。结论力尔凡联合GP方案治疗晚期非小细胞肺癌有较好疗效,通过有效的护理措施可以减轻药物带来的不良反应,提高患者的生活质量。
Objective To observe the efficacy and nursing measures of Rifan combined with GP regimen in the treatment of advanced non-small cell lung cancer (NSCLC). Methods Thirty-two patients with advanced NSCLC were randomly divided into treatment group and control group, and were treated with Rifalvan plus GP and GP respectively. The control group and the treatment group were evaluated after two consecutive cycles of chemotherapy. Results There were 16 cases in the treatment group, 7 cases in PR, 8 cases in SD and 1 case in PD. The effective rate (CR + PR) was 43.8%. The number of evaluable cases in control group was 15 cases, including 5 cases of PR, 7 cases of SD, For example, the effective rate is 33.3%. Fever patients in the treatment group had higher fever response than those in the control group, and other adverse reactions were significantly lower than those in the control group. Conclusions The combination of Rifan with GP regimen in the treatment of advanced non-small cell lung cancer has a good curative effect. Through effective nursing measures, it can reduce the side effects caused by drugs and improve the quality of life of the patients.